Skip to main content
. Author manuscript; available in PMC: 2020 Jun 19.
Published in final edited form as: Eur J Cancer. 2015 Jul 31;51(14):1978–1988. doi: 10.1016/j.ejca.2015.07.012

Fig. 1.

Fig. 1.

Venous thromboembolism (VTE), interleukin-6 (IL-6) and survival of ovarian cancer. The log-rank test or chi-square test were used to generate the P values. (A) Cumulative risk of thromboembolism after diagnosis of ovarian cancer. (B) Overall survival by stage-specific histologic subtype. (C) Overall survival after recurrence or progression by stage-specific histologic subtype. (D) Proportion of patients with IL-6 levels ≥ 10 pg/mL (prior to treatment), by stage-specific histologic subtype. (E) Progression-free survival by IL-6 level in patients with ovarian clear cell carcinoma (OCCC). (F) Progression-free survival by IL-6 level in patients with serous ovarian carcinoma (SOC). Abbreviation: HR, hazard ratio.